Health-related quality of life in patients with Waldenström macroglobulinemia: results from the ASPEN trial

• DOI: 10.1080/14796694.2024.2355079
• Publication Date: 2024-07-29T10:07:47Z
• Authors: Alessandra Tedeschi; Constantine S Tam; Roger G Owen; Christian Buske; Véronique Leblond; Meletios Dimopoulos; Ramón Garcia-Sanz; Jorge J Castillo; Judith Trotman; Steven P Treon; Keri Yang; Boxiong Tang; Heather Allewelt; Sheel Patel; Wai Y Chan; Aileen Cohen; Shengnan Chen; Gisoo Barnes
• Keywords: Male; Aged, 80 and over; Adult; Adenine; Middle Aged; 03 medical and health sciences; Pyrimidines; Treatment Outcome; 0302 clinical medicine; Piperidines; Myeloid Differentiation Factor 88; Mutation; Quality of Life; Humans; Pyrazoles; Female; Patient Reported Outcome Measures; Waldenstrom Macroglobulinemia; Rapid Communication; Aged

Aim ASPEN is a randomized, open-label, Phase III study comparing zanubrutinib and ibrutinib in patients with Waldenström macroglobulinemia (WM). Materials & methods: Patient-reported outcomes were exploratory end points assessed using the EORTC QLQ-C30 EQ-5D-5L VAS scores. Results: Overall, 201 (102 zanubrutinib; 99 ibrutinib) enrolled. Clinically meaningful differences observed diarrhea nausea/vomiting both intent-to-treat population attaining very good partial response (VGPR) earlier cycles of treatment, as well long-term physical functioning fatigue achieving VGPR. Conclusion: Treatment was associated greater improvements health-related quality life compared WM MYD88 mutations.